Imexpharm Corporation (HOSE:IMP)

Imexpharm Balance Sheet

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	303,022	161,983	106,201	178,845	271,273	85,269
Short-Term Investments	152,330	142,000	93,000	211,300	111,300	60,340
Trading Asset Securities	-	-	-	-	1,153	3,268
Cash & Short-Term Investments	455,353	303,983	199,201	390,145	383,726	148,877
Cash Growth	89.14%	52.60%	-48.94%	1.67%	157.75%	85.58%
Accounts Receivable	378,464	334,746	254,058	228,770	241,946	328,134
Other Receivables	32,485	15,014	4,066	-1,000	11,995	17,650
Receivables	410,949	349,760	258,124	227,770	255,941	345,784
Inventory	660,672	705,082	699,446	435,841	492,075	424,237
Prepaid Expenses	22,164	15,564	6,539	1,601	3,155	2,031
Other Current Assets	288,674	35,155	43,825	48,195	41,443	61,046
Total Current Assets	1,837,812	1,409,544	1,207,135	1,103,553	1,176,340	981,975
Property, Plant & Equipment	802,659	828,489	908,754	996,450	955,680	949,147
Long-Term Investments	66,959	66,959	71,284	71,290	50,962	51,669
Other Intangible Assets	73,982	74,219	74,150	72,978	73,581	76,563
Other Long-Term Assets	132,970	125,566	131,293	32,672	38,136	37,101
Total Assets	2,914,381	2,504,777	2,392,615	2,276,944	2,294,700	2,096,455
Accounts Payable	82,020	77,044	72,127	87,542	92,713	59,704
Accrued Expenses	97,529	89,231	144,776	139,803	100,346	112,446
Short-Term Debt	138,977	86,122	49,422	-	80,491	130,928
Current Portion of Long-Term Debt	-	-	-	94,980	91,652	-
Current Income Taxes Payable	20,747	31,631	19,107	25,382	17,141	12,688
Current Unearned Revenue	45,338	-	-	-	-	-
Other Current Liabilities	25,190	37,630	22,605	34,789	26,295	31,167
Total Current Liabilities	409,801	321,657	308,036	382,497	408,638	346,932
Long-Term Debt	250,000	-	-	-	91,652	-
Other Long-Term Liabilities	7,000	-	-	-	-	19,037
Total Liabilities	666,801	321,657	308,036	382,497	500,290	365,969
Common Stock	1,540,428	1,540,428	700,384	667,054	667,054	667,054
Additional Paid-In Capital	187,323	187,323	507,368	507,368	507,368	507,368
Retained Earnings	517,767	453,306	874,764	717,963	617,926	554,002
Treasury Stock	-358.6	-358.6	-358.6	-358.6	-358.6	-358.6
Comprehensive Income & Other	2,421	2,421	2,421	2,421	2,421	2,421
Shareholders' Equity	2,247,580	2,183,119	2,084,579	1,894,447	1,794,410	1,730,486
Total Liabilities & Equity	2,914,381	2,504,777	2,392,615	2,276,944	2,294,700	2,096,455
Total Debt	388,977	86,122	49,422	94,980	263,795	130,928
Net Cash (Debt)	66,375	217,862	149,779	295,165	119,931	17,949
Net Cash Growth	-45.67%	45.46%	-49.26%	146.11%	568.18%	-57.91%
Net Cash Per Share	430.98	1414.60	972.52	1916.53	778.71	119.94
Filing Date Shares Outstanding	154.01	154.01	154.01	154.01	154.01	154.01
Total Common Shares Outstanding	154.01	154.01	154.01	154.01	154.01	154.01
Working Capital	1,428,011	1,087,886	899,099	721,056	767,702	635,043
Book Value Per Share	14593.83	14175.27	13535.33	12300.70	11651.16	11236.10
Tangible Book Value	2,173,598	2,108,900	2,010,429	1,821,469	1,720,829	1,653,923
Tangible Book Value Per Share	14113.45	13693.36	13053.86	11826.85	11173.39	10738.97
Buildings	384,650	384,650	384,597	299,061	298,602	262,381
Machinery	1,096,676	1,088,549	1,066,310	638,041	601,972	578,380
Construction In Progress	35,381	43,897	47,351	580,743	519,463	522,447

Updated Jan 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.